Immunoassay Market Size Expected to Reach USD 53,970 Million by 2034 with 5.1% CAGR | Statifacts Report

According to Statifacts, the global Immunoassay market size is calculated at USD 32,820 million in 2024 and is expected to reach around USD 53,970 million by 2034, growing at a CAGR of 5.1% for the forecasted period.

Ottawa, Feb. 13, 2025 (GLOBE NEWSWIRE) -- The global Immunoassay market is estimated to reach a valuation of USD 34,490 million in 2025 and is expected to grow at a CAGR of 5.1% during the forecast period of (2025 to 2034), a study published by Statifacts a sister firm of Precedence Statistics.

Elevate your business strategy with market-driven insights—purchase the report today (Price USD1550) https://www.statifacts.com/order-report/7123

The increasing emphasis on sustainable and environmentally friendly practices in chemistry, necessary for measuring pollutants and contaminants, contributes to adopting biochemical tests for environmental monitoring.

The expanding role of biochemical tests in material science applications drives market growth, particularly in designing and optimizing materials. The trend of drug repurposing, where existing drugs are explored for new therapeutic indications and potential side effects are measured, boosts the need for sophisticated drug development approaches. Growing collaboration among research institutions and pharmaceutical companies amplifies the utilization of biochemical tools, contributing to market growth. The shift towards personalized medicine drives the demand for tailored drug design, creating opportunities for clinical diagnostics solutions. Biochemical tools play a crucial role in predicting and assessing the toxicity of chemical compounds, supporting advancements in toxicology studies. The agriculture sector's increasing focus on chemical research for crop protection and enhancement fuels the growth of eco-friendly applications. Stricter regulatory requirements in pharmaceutical and chemical industries drive the adoption of biochemical tools for compliance and documentation. International collaborations and the globalization of research initiatives contribute to their widespread adoption.  The increasing focus on rare diseases prompts the use of these tests in identifying potential treatments and accelerating drug development. The preference for open-source immunoassay platforms increases, fostering community-driven development and accessibility. The expansion of the biotechnology industry further propels the demand for these diagnostic tools in areas like genomics and proteomics. The complexity of integrating diverse chemical data sources boosts the need for advanced immunoassay solutions for seamless data handling. Rising investments and funding in chemical and pharmaceutical research provide the financial support necessary for developing and adopting innovative immunoassay technologies.

The integration of AI increases focus on drug development and discovery, a crucial driver for the growing demand for advanced immunoassay tools. As researchers seek to innovate and expedite the drug design process, the importance of sophisticated computational methodologies has never been clearer. Recent breakthroughs in computational technologies significantly enhance the efficiency and functionality of biochemical tools, thereby promoting the expansion of this market. Moreover, incorporating big data analytics within the immunoassay market is revolutionizing how researchers handle and interpret vast amounts of data. This capability allows for more thorough research processes, enabling scientists to uncover previously elusive insights due to data constraints. Integrating large-scale datasets facilitates a more nuanced understanding of chemical interactions and properties, essential for advancing drug development.

Simultaneously, the field of computational chemistry is experiencing a surge in popularity, further contributing to the demand for robust biochemical tools. As the discipline evolves, there is an increasing need for sophisticated data analysis and modeling techniques that can support complex chemical phenomena. In addition, integrating machine learning algorithms into immunoassay platforms marks a significant advancement in predictive modeling and decision-making abilities. These algorithms enable more accurate predictions of molecular behavior and interactions, which can significantly streamline the drug development process. As the landscape of drug discovery becomes increasingly competitive, the capacity to leverage these advanced technologies will be pivotal in achieving success. Overall, the interplay of these factors propels the ongoing growth and innovation within the field of immunoassay.

• For instance, in February 2024, SYNTHIA^TM retrosynthesis software will help organic chemists innovate robust synthetic routes using expert-coded rules and AI-powered algorithms.
  

Immunoassay Market Report Scope

Report Attribute	Details
Market size value in 2025	USD 34,490 Million
Revenue forecast in 2034	USD 53,970 Million
Growth rate	CAGR of 5.1% from 2024 to 2034
Base year for estimation	2023
Historical data	2018 - 2024
Forecast period	2025 - 2034
Quantitative units	Revenue in USD million/billion and CAGR from 2024 to 2034
Report coverage	Revenue forecast, company ranking, competitive landscape, growth factors, trends
Segments covered	Product, specimen, technology, application, end-use, region
Regional scope	North America; Europe; Asia Pacific; Latin America; MEA
Country scope	U.S.; Canada; Germany; UK; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; South Korea; Australia; Thailand; Brazil; Mexico, Argentina; South Africa; Saudi Arabia, UAE; Kuwait
Key companies profiled	Siemens Healthineers ; bioMérieux SA; Abbott ; Danaher Corporation (Beckman Coulter); Quidel Corporation; Ortho Clinical Diagnostics; Sysmex Corporation; Bio-Rad Laboratories , Inc.; Becton, Dickinson, and Company; F. Hoffmann-La Roche AG; Thermo Fisher Scientific , Inc.

Immunoassay Market Trends

• Demand for diagnostic tests:
  

CLIA diagnostic tests are crucial in detecting patients who have cancer and diabetes. The growing global population and an increase in chronic diseases are significantly driving up the demand for these essential diagnostic tools. In response to this heightened demand, ongoing research and development in CLIA technology fosters the innovation of new products with enhanced performance and efficiency. Innovations in this field may include improved sensitivity, which requires convenient testing to achieve accurate diagnostic tests.

• Incorporation of Technological advancements
  

The integration of technologies such as CLEIA, Enzyme-Linked Immunosorbent Assay (ELISA), and Radioimmunoassay (RIA) with conventional drug development, particularly in areas such as chronic disease and veterinary diagnostics presents a promising avenue for growth. This holistic approach can enhance patient comfort, reduce pharmaceutical reliance, and improve drug development. Continued research and development aimed at scientifically validating the efficacy and safety of biochemical tests can also play a crucial role in addressing existing concerns. By establishing robust clinical evidence and integrating advanced technologies into mainstream drug development and research practices, the credibility of this natural treatment can be significantly enhanced, fostering greater acceptance and use to research and monitor sensitive testing.

Buy this Databook (Price USD1550) https://www.statifacts.com/order-report/7123

Segments Insights

Product Insights

The immunoassay market is dominated by the reagents and kits segment. Integrating AI in developing kits has enhanced the diagnosis and monitoring of respiratory diseases, protecting medical professionals and patients from infecting each other during check-up sessions.

The software and services segment is the fastest-growing segment in the immunoassay market. The rising popularity of software solutions is particularly evident among biochemical tests. Moreover, they facilitate real-time collaboration, enabling faster security software and Laboratory Information System (LIS) times, which are crucial for data transfer. These innovations would allow organizations to enhance efficiency and accuracy while diminishing the risks associated with drug development. As many companies emphasize large-scale collaboration to navigate ongoing industry changes, these technological advancements open up promising growth opportunities for key market players.

Technology Insights

The enzyme immunoassays segment dominated the immunoassay market. This method uses an enzyme bound to an antigen or antibody that identifies and measures substances. The test method provides information about diseases that can be tackled with proper treatment. The enzyme-linked immunosorbent assay (ELISA) and enzyme multiplied immunoassay technique (EMIT) detect antibodies and antigens by forming an enzyme-triggered color change in the provided sample.

The rapid tests segment is the fastest-growing market since they are low and cost-effective methods that can be used for various purposes such as screening, diagnosis, and monitoring various diseases. The test can detect proteins from the virus by swabbing the nose and throat area. They can also detect an antigen (a type of protein) produced by the SARS-CoV-2 virus. The test aims to block the binding sites on the antibodies on the test line and prevent their reaction with the colored conjugate.

By End-use Insights

The hospital segment dominated the immunoassay market since the hospitals provide diagnostic tests and treatment to patients. The routine check-ups and integration of technology have enhanced and improved hospital services. The patients are monitored through VR tools, and their medications are updated using AI-driven data. Hospitals offer an extensive array of services that encompass everything from accurate diagnosis to comprehensive treatment options. Equipped with advanced medical instruments and cutting-edge technology, these facilities ensure that patients receive the highest standard of care. The combination of skilled healthcare professionals and specialized equipment makes hospitals a top choice for individuals seeking medical attention and support during their health journeys.

The clinical laboratories segment is the fastest-growing segment in the immunoassay market. It dominates due to increasing drug investigation requirements. The major factors driving the clinical laboratories segment in the pharmaceutical sector are product protocols and supply chain management. The safety of biochemical tools is most important in the pharmaceutical segment. Clinical laboratories also have permission to collect data on drug development for research and purposes and analyze test performance.  

Regional Insights

North America dominates the immunoassay market due to the rise in global population, which significantly increases the prevalence of chronic conditions. This rise in chronic cases often leads to serious complications. Fortunately, advancements in screening methods and a growing awareness of these diseases have initiated efforts toward earlier detection and intervention, boosting the market demand. By identifying at-risk individuals sooner, healthcare providers can implement treatment strategies that may slow the progression of the disease. As awareness continues to grow, patients and healthcare systems must prioritize early screening and management to mitigate adverse outcomes associated with antibodies within the patient potentially.

Asia-Pacific is the fastest-growing region in the immunoassay market due to ongoing research and development efforts exploring new drugs, gene therapies, and regenerative medicine approaches, which could provide more effective treatment options for patients suffering from chronic disease. Moreover, telemedicine presents a promising avenue for enhancing patient monitoring and engagement. By utilizing telehealth technologies, healthcare providers can improve treatment adherence, provide timely interventions, and facilitate better overall disease management for individuals. As these new methods and technologies continue to evolve, they can potentially transform the landscape of immunoassay treatment and diagnostic tests and improve patient outcomes significantly.

Elevate your business strategy with market-driven insights—purchase the report today (Price USD1550) https://www.statifacts.com/order-report/7123

You can place an order or ask any questions, please feel free to contact us at sales@statifacts.com

Immunoassay Market Top Key Companies:

• Abbott
• Siemens Healthineers
• Danaher Corporation (Beckman Coulter)
• bioMérieux SA
• Quidel Corporation
• Sysmex Corporation
• Ortho Clinical Diagnostics
• Bio-Rad Laboratories , Inc.
• F. Hoffmann-La Roche AG
• Becton, Dickinson, and Company
• Thermo Fisher Scientific , Inc.
  

Immunoassay Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2019 to 2034. For this study, Statifacts has segmented the global Immunoassay Market

By Product

• Reagents & Kits
  • ELISA Reagents & Kits    
  • Rapid Test Reagents & Kits          
  • ELISPOT Reagents & Kits              
  • Western Blot Reagents & Kits    
  • Other Reagents & Kits  
• Analyzers/Instruments
  • Open Ended Systems
  • Closed Ended Systems
• Software AG & Services

By Specimen

• Blood  
• Saliva    
• Urine    
• Other Specimens      

By Technology

• Radioimmunoassay (RIA)
• Enzyme Immunoassays (EIA)Rapid Test
  • Chemiluminescence Immunoassays (CLIA)
  • Fluorescence Immunoassays (FIA)
• Others
  

By Application Outlook (Revenue, USD Million, 2018 - 2030)

• Therapeutic Drug Monitoring
• Oncology
• Cardiology
• Endocrinology
• Infectious Disease Testing
• Autoimmune Diseases
• Others
  

By End-use

• Hospitals
• Blood Banks
• Clinical Laboratories
• Pharmaceutical and Biotech Companies
• Academic Research Centers
• Others

• By Regional
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East Africa

Elevate your business strategy with market-driven insights—purchase the report today (Price USD1550) https://www.statifacts.com/order-report/7123

Browse More Research Reports ;

• U.S. Pharmaceutical Water Market ; The U.S. pharmaceutical water market size accounted for USD 7,090 million in 2024 and is predicted to touch around USD 16,950 million by 2034, growing at a CAGR of 9.11% from 2025 to 2034.
• U.S. Pharmaceutical Market : The U.S. pharmaceutical market size is calculated at USD 634.34 billion in 2024 and is predicted to attain around USD 1,107.4 billion by 2034, expanding at a CAGR of 5.73% from 2025 to 2034.
• U.S. Corporate Wellness Market : The U.S. corporate wellness market size surpassed USD 22,160 million in 2024 and is predicted to reach around USD 42,390 million by 2034, registering a CAGR of 6.7% from 2025 to 2034.
• U.S. Revenue Cycle Management Market : The U.S. revenue cycle management market size accounted for USD 58.55 billion in 2024 and is expected to exceed around USD 183.48 billion by 2034, growing at a CAGR of 12.1% from 2025 to 2034.
• U.S. Life Science Tools Market  : The U.S. life science tools market size accounted for USD 50.01 billion in 2024 and is expected to exceed around USD 187.03 billion by 2034, growing at a CAGR of 14.1% from 2025 to 2034.
• U.S. Healthcare Personal Protective Equipment Market : The U.S. healthcare personal protective equipment market size is calculated at USD 7,260 million in 2024 and is predicted to reach around USD 10,140 million by 2034, expanding at a CAGR of 3.4% from 2025 to 2034.
• U.S. Preclinical CRO Market : The U.S. preclinical CRO market size accounted for USD 2,120 million in 2024 and is expected to exceed around USD 4,660 million by 2034, growing at a CAGR of 8.2% from 2025 to 2034.
• U.S. AI in Life Science Analytics Market : The U.S. AI In life science analytics market size was estimated at USD 594 million in 2024 and is projected to be worth around USD 1,732.76 million by 2034, growing at a CAGR of 11.3% from 2025 to 2034.
• U.S. Biologics Market : The U.S. biologics market size accounted for USD 192.41 billion in 2024 and is predicted to touch around USD 407.77 billion by 2034, growing at a CAGR of 7.8% from 2025 to 2034.
• U.S. Disposable Face Mask Market : The U.S. disposable face mask market size is calculated at USD 356.90 million in 2024 and is predicted to attain around USD 735.58 million by 2034, expanding at a CAGR of 7.50% from 2025 to 2034.

You can place an order or ask any questions, please feel free to contact us at sales@statifacts.com

Statifacts offers subscription services for data and analytics insights. This page provides options to explore and purchase a subscription tailored to your needs, granting access to valuable statistical resources and tools. Access here - https://www.statifacts.com/get-a-subscription

Contact US

• Ballindamm 22, 20095 Hamburg, Germany
• Email: sales@statifacts.com
• Web: https://www.statifacts.com/
• Europe : +44 7383 092 044
  

About US

Statifacts is a leading provider of comprehensive market research and analytics services, offering over 1,000,000 market and custoer data sets across various industries. Their platform enables businesses to make informed strategic decisions by providing full access to statistics, downloadable in formats such as XLS, PDF, and PNG.

For Latest Update Follow Us:

Statifacts | Precedence Research| Towards Healthcare